Raymond James Financial
IPSC icon

Raymond James Financial’s Century Therapeutics IPSC Stock Holding History

Raymond James Financial’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Hold
91,323
– – ﹤0.01% 4989
2026
Q1 		$206K Hold
91,323
– – ﹤0.01% 4872
2025
Q4 		$90.8K Hold
91,323
– – ﹤0.01% 4945
2025
Q3 		$45.5K Hold
91,323
– – ﹤0.01% 4834
2025
Q2 		$51K Buy
+91,323
New +$49K ﹤0.01% 5174

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Raymond James Financial's IPSC Position: Q2 2026 in Review

Raymond James Financial held its Century Therapeutics (IPSC) position steady in Q2 2026 at 91,323 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #4989.

Raymond James Financial first reported a position in IPSC in Q2 2025 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Raymond James Financial held 91,323 shares of Century Therapeutics worth $224K as of Q2 2026.
  • Raymond James Financial left its Century Therapeutics share count unchanged in Q2 2026.
  • Century Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4989 holding.
  • Raymond James Financial first reported a position in Century Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 100 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.